BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

Post-LOE

buprenorphine and naloxone

Ascentage Pharma

ANDASUBLINGUALTABLET

Approved

Sep 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (buprenorphine and naloxone) by Ascentage Pharma is partial opioid agonists [moa]. Approved for opioid dependence. First approved in 2016.

Drug data last refreshed 1w ago

Mechanism of Action

Partial Opioid Agonists

Pharmacologic Class:

Partial Opioid Agonist

Indications (1)

opioid dependence

Company

Worked on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.